SCHEMBL8775934

SCHEMBL8775934

C=C1/C(=C\C=C2/CCC[C@]3(C)C([C@H](C)C=O)CC[C@@H]23)C[C@@H](C)C[C@@H]1OP

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 10/20 0.51
ADRA1A P35348 2/20 0.50
ADORA3 P0DMS8 2/20 0.50
SLC6A2 P23975 2/20 0.50
NR1I2 O75469 1/20 0.50
PGR P06401 1/20 0.50
HTR1A P08908 1/20 0.50
SLC6A4 P31645 1/20 0.50
PTGS2 P35354 1/20 0.50
LMNA P02545 2/20 0.49
AR P10275 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
CYP3A4 P08684 1/20 0.49
USP2 O75604 1/20 0.49
ABCB11 O95342 1/20 0.49
ESR1 P03372 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14501677 0.88 VDR (0.55) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL14415915 0.88 VDR (0.55) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL14501672 0.88 VDR (0.55) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL8775963 0.87 VDR (0.56) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL8775972 0.87 VDR (0.56) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL8775979 0.87 VDR (0.56) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL8775803 0.86 VDR (0.55) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL12798575 0.86 VDR (0.47) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL8775984 0.86 VDR (0.47) VDRADRA1AADORA3SLC6A2NR1I2
SCHEMBL8775848 0.84 VDR (0.51) VDRADRA1AADORA3SLC6A2NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120130133-A1 Method For Synthesizing Vitamin D Analogs CYTOCHROMA INC. (CA) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130133-A1 Method For Synthesizing Vitamin D Analogs VDR, CYP24A1, CYP2R1 VDR 1/4885ADRA1A 4068/4885ADORA3 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.